Cargando…
Improving Antibody‐Tubulysin Conjugates through Linker Chemistry and Site‐Specific Conjugation
Tubulysins have emerged in recent years as a compelling drug class for delivery to tumor cells via antibodies. The ability of this drug class to exert bystander activity while retaining potency against multidrug‐resistant cell lines differentiates them from other microtubule‐disrupting agents. Tubul...
Autores principales: | Hamilton, Joseph Z., Pires, Thomas A., Mitchell, Jamie A., Cochran, Julia H., Emmerton, Kim K., Zaval, Margo, Stone, Ivan J., Anderson, Martha E., Jin, Steven, Waight, Andrew B., Lyon, Robert P., Senter, Peter D., Jeffrey, Scott C., Burke, Patrick J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048973/ https://www.ncbi.nlm.nih.gov/pubmed/33369163 http://dx.doi.org/10.1002/cmdc.202000889 |
Ejemplares similares
-
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016) -
Optimization of Tubulysin Antibody–Drug Conjugates:
A Case Study in Addressing ADC Metabolism
por: Tumey, L. Nathan, et al.
Publicado: (2016) -
Antibody–drug conjugates: Recent advances in linker chemistry
por: Su, Zheng, et al.
Publicado: (2021) -
Convenient methods for preparing π-conjugated linkers as building blocks for modular chemistry
por: Kulhánek, Jiří, et al.
Publicado: (2009) -
Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2
por: Faria, Morse, et al.
Publicado: (2019)